Brind.

Immunovant, Inc. presented new company data at the meeting of the American Thyroid Association (ATA).

3 reports, 1 independent Updated Sep 4
Gone quiet
Reports
3
Developments
2
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Immunovant, Inc. presented new company data at the meeting of the American Thyroid Association (ATA).

Who's involved

What this event is mainly about
American Thyroid Association

How it developed

Newest first. Tap a step to see who reported it.
  1. Immunovant developed and tested batoclimab, which is currently being studied for the treatment of Graves’ disease.Sub-event
  2. Immunovant presented company data at the ATA meeting on September 4, 2025.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireRoivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients First-ever potentially disease-modifying t
  • GlobeNewswireImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a
  • Unknown outlet